|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||6.23 - 6.31|
|52-week range||6.23 - 6.31|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||0.02|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.